###### Strengths and limitations of this study

-   Review protocol adopts the following quality standards---independent study selection, data extraction, risk of bias assessments by two researchers---as informed by the Centre of Reviews and Dissemination guidance and PRISMA-P guidelines.

-   The first review to be conducted with a secondary aim of examining factors related to successful participant recruitment into psychological interventions trials for dementia and mild cognitive impairment.

-   To increase quality of included studies and reduce methodological heterogeneity, studies with high risk of bias (following Cochrane Collaboration guidance) concerning method of random sequence generation and allocation concealment were excluded.

-   Owing to resource limitations, selected studies were limited to those publically available in the English language; therefore, language bias may be present.

-   High levels of clinical heterogeneity may exist as a consequence of included studies adopting psychological interventions informed by a variety of psychological approaches and including participants with different dementia types and levels of cognitive impairment.

Introduction {#s1}
============

While healthcare advances across the developed world have resulted in increased life expectancy,[@R1] increased numbers of people are also placed at risk of developing chronic health conditions.[@R2] As such, dementia, a common chronic condition associated with ageing,[@R3] has become of significant concern. Current estimates of people living with dementia worldwide are in excess of 35 million, set to double by 2030, and more than triple by 2050.[@R4] In the absence of a cure for dementia, or identification of specific causal factors as targets for preventative interventions,[@R5] dementia care strategies are focused on providing appropriate psychological and psychosocial support, alongside the provision of physical care.[@R6] However, access to evidence-based psychological therapies to improve the long-term psychological well-being and mental health-related quality of life in people with dementia is currently limited.[@R7]

Elevated symptoms of depression in people with dementia are common with prevalence reported to be as high as 30[@R8] [@R9]--50%,[@R10] compared to 13.2% of older adults without cognitive impairment.[@R11] However, the prevalence of depression in people with dementia should potentially be considered with caution. Rates of depression may vary across dementia type, with a small number of studies indicating prevalence rates higher in patients experiencing dementia with Lewy bodies and vascular dementia, in comparison with Alzheimer\'s disease.[@R8] Large variations in rates of depression in Alzheimer\'s disease have also been found when a stricter criterion is adopted with respect to meeting a diagnosis of major depression.[@R12] Studies adopting International Classification of Diseases (ICD) 10 criteria have found rates of 5[@R13]--14% using DSM-IV criteria,[@R14] and 38[@R15]--44%[@R14] when using the National Institutes of Mental Health (NIMH) proposed standardised diagnostic criteria for depression in Alzheimer\'s disease.[@R16] Such wide variations in prevalence rates may be due to the differences in depressive symptom presentation in people with dementia and variation diagnostic criterion used in these tools.[@R12] In relation to mild cognitive impairment (MCI) rates of mild depressive symptoms have varied from 26.5%[@R17] to 49.3%,[@R18] with 14% experiencing severe depressive symptoms.[@R18] Furthermore, prevalence of elevated symptoms of anxiety have been found to range from 8% to 71%,[@R19] with 5--21% of people with a dementia meeting diagnostic criteria for a specific anxiety disorder.[@R20] However, there is little consensus concerning how to define and measure anxiety experienced by people with a dementia.[@R9] Rates of anxiety symptoms have also been found to vary widely in MCI (10--74%).[@R21]

Despite variability reported regarding the prevalence of depression and anxiety in people with dementia and MCI,[@R9] [@R12] a clear need remains for evidence-based psychological therapies to address these difficulties. However, only six studies were identified in a Cochrane review examining the effectiveness of psychological interventions specifically targeting depression or anxiety.[@R9] Other reviews have tended to focus on the effectiveness of non-pharmacological interventions for a variety of neuropsychiatric symptoms in severe or very severe dementia.[@R22] Furthermore, while depression and anxiety have a significant impact on the lives of people with dementia and MCI, the negative impact of these psychological difficulties extend beyond their symptomatology alone.[@R8] For depression and anxiety, symptoms have been associated with reduced quality of life,[@R8] [@R23] increased likelihood of being placed in a nursing home or other institution,[@R24] [@R25] and caregiver burden.[@R26] [@R27] Furthermore, specifically with respect to depression, higher rates of cognitive decline have been reported,[@R28] with increased behavioural disturbances associated with anxiety.[@R29]

As such, the need to develop evidence-based psychological interventions to support the long-term emotional needs of people experiencing dementia, and examine their impact on difficulties beyond those related solely with depression and anxiety, is justified. Developing interventions that enable people with dementia to 'live well' is a priority with the UK National Dementia strategy,[@R30] with recent research focusing on improving general well-being and quality of life to facilitate people to 'live well' with dementia.[@R31] However, research on dementia has previously adopted a disease-focused model, rather than a focus on longer term well-being and quality of life.[@R32] Indeed, a limitation of existing literature is that interventions tend to overlook outcomes relating to quality of life and general psychological well-being.[@R33] This is of particular importance considering the elevated stigma associated with mental health difficulties in older adult physical health populations,[@R34] and associated low levels of help-seeking regarding mental health support.[@R35] [@R36] One reason for low levels of help-seeking behaviour may relate to the greater identification of physical health populations with the experience of general distress as a response to illness,[@R37] as opposed to a specific mental health difficulty, such as depression or anxiety. Subsequently, previous reviews focusing on interventions targeting medicalised constructs, such as depression or anxiety,[@R9] may have omitted the evidence base concerning psychological interventions targeting broader constructs relating to general psychological distress and well-being.

Currently, there are no systematic reviews examining the evidence base of psychological interventions targeted at improving general psychological well-being or mental health-related quality of life in people with dementia and MCI.[@R38] While a recent review[@R9] has examined the effectiveness of psychological interventions for people with dementia and MCI targeting depression and anxiety, this current review protocol widens the scope by also including interventions targeting general psychological distress and quality of life. Further, results of this review will allow the independent triangulation of results obtained by this previous review.[@R9]

As well as establishing the evidence base for psychological interventions targeting general psychological well-being in people with dementia or MCI, it may also be prudent to investigate clinical and methodological characteristics associated with these studies. A number of complexities have been identified when recruiting participants into pharmaceutical trials associated with dementia or MCI, including capacity to consent, and the presence of physical or neuropsychiatric symptoms impacting on eligibility.[@R38] Furthermore, a number of known barriers exist regarding recruiting older adults into psychological intervention trials, including stigma concerning mental health difficulties experienced by older adults,[@R39] preoccupation with physical health symptoms,[@R42] and lack of healthcare professional recognition.[@R43] Participants and professionals have also been found to view participation in depression trials with greater caution for older rather than younger adults, and for people with physical health conditions.[@R44] With respect to anxiety, symptoms are frequently unrecognised in older adults, given they often do not conform to existing diagnostic criteria.[@R45] Additionally, elevated stigma exists concerning anxiety in older adults in comparison with other mental health conditions, including depression.[@R41]

Greater understanding of methodological factors may, therefore, help inform successful recruitment strategies into subsequent studies aiming to examine the effectiveness of psychological interventions for people with dementia and MCI to improve psychological well-being. A recent systematic review examining recruitment in pharmacological trails for Alzheimer\'s disease has suggested 10% of potential participants would take part in clinical drug trials if all those diagnosed were invited to participate.[@R38] However, currently, no reviews exist examining factors related to successful recruitment into psychological interventions for dementia. The present systematic review, therefore, aims to identify clinical and methodological moderators associated with effectiveness and recruitment strategies for trials involving people with dementia and MCI, alongside examining the overall effectiveness of psychological interventions to improve psychological well-being.

Objectives {#s2}
==========

1.  To examine the effectiveness of psychological interventions targeted at improving psychological and emotional well-being and mental health-related quality of life, compared with active and inactive control conditions, in adults with dementia or MCI.

2.  To investigate clinical and methodological moderators associated with effectiveness.

3.  To identify recruitment techniques and effectiveness of the techniques used across trials.

Methods and analysis {#s3}
====================

The Centre of Reviews and Dissemination (CRD) guidance for conducting systematic reviews,[@R46] will be followed, with results of the review reported in accordance with PRISMA-P guidelines.[@R47] The review is registered with the PROSPERO International Prospective Register of Systematic Reviews (registration number CRD42015025177).

Study inclusion and exclusion criteria {#s3a}
--------------------------------------

### Type of studies {#s3a1}

Randomised controlled trials (RCTs) and cluster RCTs, using a method of random sequence generation with allocation concealment assessed as having low or unclear risk of bias using the Cochrane Collaboration Risk of Bias tool,[@R48] will be eligible for inclusion. This is to help minimise the inclusion of studies of low quality with high of selection bias known to inflate effect sizes[@R49] [@R50] and is a technique used in a number of other systematic reviews and meta-analyses.[@R51] Quasi-RCTs and cross-over trials will not be eligible for inclusion.

### Types of participants {#s3a2}

Adults with diagnosis of a dementia by the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV or DSM-5 (American Psychiatric Association (APA[@R54] [@R55]) ICD-10[@R56] alternative validated diagnostic criteria, or recorded in their medical records. Alzheimer\'s disease, vascular dementia, dementia with Lewy bodies and frontotemporal dementia and will be eligible for inclusion. In addition, adults with a diagnosis of MCI, a term used to describe a person experiencing problems with cognitive function, but with such difficulties not being severe enough to currently attract a diagnosis of dementia, will be eligible for inclusion. Valid methods of diagnosis adopted for MCI will include: DSM-5 criteria,[@R55] Petersen's criteria (P-MCI,[@R57]), alternative validated diagnostic criteria, or where recorded in medical records. No limitations will be placed on the severity of dementia, length of time since diagnosis, with dementia patients in community and institutional settings eligible. No restrictions will be placed on severity of depression, anxiety, psychological distress or mental health-related quality of life.

### Types of interventions {#s3a3}

The review will include any psychological therapy and includes specific interventions with no limitations placed on the psychological therapy model informing the intervention. Psychological therapies eligible for inclusion will use specific therapeutic principles and techniques hypothesised to target an improvement in psychological well-being or a reduction in symptoms associated with psychological difficulties. Psychological therapies eligible for inclusion may include, but is not restricted to: cognitive--behavioural therapies; behavioural interventions; social skills training; relaxation therapy; psychodynamic; humanistic/counselling approaches; and interpersonal therapies. The intervention should target an improvement in general psychological well-being as identified by measurement of depression, anxiety, psychological distress or mental health-related quality of life. As long as the intervention is targeted at improving psychological well-being in the person with dementia or MCI, dyadic interventions that may additionally target the informal carer will also be eligible. Additionally, all intervention delivery modes (individual, group or dyadic) and methods of support (face to face, telephone, internet) will be eligible for inclusion. There will be no limitations placed on the professional background of the person supporting the intervention; additionally unsupported (self-guided/self-administered) interventions will also be eligible for inclusion.

Both inactive and active comparators will be considered eligible. However, the trial design must allow for the isolation of the effect of the psychological intervention of interest. Examples of appropriate designs are as follows: Psychological intervention versus control (no-treatment control; wait-list control; treatment as usual);Psychological intervention versus non-specific factor component control,[@R58] (eg, where therapist time is equivalent to that provided in the experimental arm but only non-specific factors are provided as an intervention);Psychological intervention plus medication versus medication;Psychological intervention plus information versus information.

### Types of settings {#s3a4}

There will be no restriction placed on setting of intervention delivery. For example, studies where the intervention was delivered in primary care, secondary care, university-based clinics, homes, residential care homes and community settings will all be included.

### Types of outcome measures {#s3a5}

Studies eligible for inclusion will use one or more of the following self-report, clinician or proxy administered primary outcome measurements: (1) standardised measurement of depression (eg, the Beck Depression Inventory, BDI-II,[@R59]); (2) standardised measurement of anxiety, (eg, the Beck Anxiety Inventory, BAI[@R60]); (3) standardised measurement of psychological distress, defined as a measurement of general psychiatric distress including domains of mental health-related symptoms such as depression, anxiety, insomnia and somatic symptoms (eg, the General Health Questionnaire, GHQ[@R61]); or (4) standardised measurement of quality of life if they include a mental health-specific subscale or domain (eg, the SF-36[@R62]) or the Alzheimer disease-related quality of life (ADRQL[@R63]). Where multiple time points are reported, a primary end point ≤6 months post-treatment will be adopted to minimise the likelihood bias associated with examining short-term post-treatment effects only that are likely to result in higher effect sizes.[@R64] [@R51] [@R65] However, outcomes for all time points reported in the included studies will be extracted to enable a potential moderator analysis on length of follow-up.

Search methods for identification of studies {#s3b}
--------------------------------------------

### Electronic searches {#s3b1}

The following electronic databases will be searched: Cumulative Index to Nursing and Allied Health Literature (CINAHL); Excerpta Medica DataBase (EMBASE); PsychInfo; MEDLINE; Applied Social Sciences Index and Abstracts (ASSIA) and the Cochrane Central Register of Controlled Trials (CENTRAL). A comprehensive search strategy was developed using medical subject headings (MeSH). The Ovid MEDLINE search strategy can be found in online supplementary file 1. No limitations will be placed on year of publication, and only studies which are publically available in the English language will be eligible for inclusion due to limited resources to funding translation services.

### Searching other resources {#s3b2}

The reference lists and citations of all included studies will be hand searched for further eligible studies. In addition, journals containing the highest numbers of included studies will be hand searched for recent potentially eligible publications (≤12 months). Experts in the field will also be contacted to identify any unpublished or ongoing trials.

Data collection and analysis {#s3c}
----------------------------

### Selection of studies {#s3c1}

Two researchers will act as reviewers and screen titles and abstracts. Full paper reviews will be conducted independently to determine inclusion with all discrepancies initially discussed. If consensus cannot be reached, a third member of the research team (PF) will be contacted. An Excel spreadsheet has been developed to manage all review data.

### Data extraction and management {#s3c2}

Following guidance,[@R46] data will be double extracted by the two reviewers (JW and MA) using a data extraction form developed in Excel for this review, with discrepancies discussed and the third member of the review team (PF) contacted if consensus is not reached. Study characteristics will be extracted from published papers, with study authors contacted in the event of missing data. In addition to the extraction of standard study information (study identification features, study characteristics, primary outcome measurements, statistical approaches and primary results) the following information will also be extracted: *Participant characteristics*: dementia subtype (eg, Alzheimer\'s disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, MCI); how diagnosis of dementia or MCI was established (eg, patient record check or in-trial procedures; validated diagnostic tool for dementia used (eg, DSM-IV, DSM-V or ICD-10); global severity of dementia; severity of cognitive impairment; severity of behavioural and psychological symptoms of dementia; time since diagnosis; physical health comorbidities; neuropsychiatric comorbidities; age; gender; ethnicity; educational status; support from an informal carer (yes/no).*Intervention characteristics*: psychological model (eg, cognitive therapy, behavioural therapy, interpersonal therapy; psychoeducation; problem-solving; psychosocial support; relaxation); mode of delivery (eg, individual, group, dyadic); type of support (eg, face-to-face, telephone, email); treatment setting (eg, community, care home, primary care, secondary care); clinician delivering treatment; intervention-specific training of clinicians delivering the treatment; treatment duration; number of sessions; length of sessions; manualised treatment and measurement of treatment integrity.*Recruitment characteristics*: patient or dyadic (patient and carer); type of consent (eg, informed, proxy); sampling method; recruitment setting (eg, clinical, community, mixed); type of recruitment (eg, mail-out, physician/healthcare professional referral, advertisement); number of participants invited, number of participants screened, number of participants eligible, number of participants randomised, reasons for non-eligibility, whether respondent characteristics match the target population defined as response rate ≥80% or appropriate analysis comparing respondent and non-respondent characteristics.[@R38]*Statistical approaches and primary results*:  4.1 Consistent with the aims of intention-to-treat analysis, any outcome information available for patients excluded from the original analysis will also be extracted.  4.2 For cluster trials, estimates of intracluster correlation coefficients (ICC) and average cluster sizes will be gathered, which are potentially needed for revised analyses (see Unit of analysis issues section).  4.3 Within-study correlations between different outcomes will be extracted, where available, to inform on the simultaneous effects of treatment on the outcomes of interest in the same participants.

Assessment of risk of bias {#s3d}
--------------------------

The methodological quality of included studies will be examined independently by the two reviewers using the Cochrane Collaboration\'s Risk of Bias tool.[@R48] Study quality ratings will be compared, discrepancies discussed, and the third reviewer (PF) contacted if consensus is not reached. Specifically, selection, performance, attrition and reporting bias will be examined. Reporting bias will be examined by making efforts to obtain study protocols (eg, obtaining published protocols, checking trial databases or requesting from study authors) and comparing outcomes reported in the protocol with those reported in the paper. Additionally, comparisons will be made between outcomes reported in the methods and results sections of trial reports. Study authors will be contacted in the event of any discrepancy to identify potential changes to the study protocol and request any missing data. For cluster-randomised trials, studies will be examined for 'unit-of-analysis' errors,[@R66] [@R67] whereby groups were randomised in the trial, but individuals were treated as the randomised units in analysis. Cluster trials will also be assessed for 'recruitment bias' in which individuals are recruited after cluster randomisation, with knowledge of cluster allocation.[@R68]

Data synthesis and statistical analysis {#s3e}
---------------------------------------

### Measures of treatment effect {#s3e1}

If available data permits, a meta-analysis will be conducted using 'metafor' package in R.[@R69] Hedges' g will be calculated to determine the post-treatment between-group standardised mean effect size from outcomes relating to depression, anxiety, psychological distress and mental health-related quality of life separately. In cases reporting multiple time points, the longest follow-up time point will be adopted ≤6 months. Comparisons will be analysed separately with control condition sample size halved for studies where two treatments eligible for inclusion are compared with one control condition. Likewise, for studies comparing two control conditions with one treatment condition, comparisons will be analysed separately with the sample size in the treatment condition halved. A random effects model will be adopted as wide variations in treatment, participant characteristics and methodological factors are expected between the studies.[@R70] [@R71]

### Unit of analysis issues {#s3e2}

For cluster RCTs, if clustering was not appropriately considered in the original analysis, estimates of ICC and average cluster sizes will be used to increase the SEs appropriately.[@R68] If the required information cannot be obtained from source, authors will be contacted directly, or values borrowed from similar studies if possible.

### Summary proportions {#s3e3}

To examine recruitment and data permitting, summary proportions will be calculated.[@R69] Effects will be reported as proportions but transformed to log (odds) for the purposes of the meta-analysis. Specifically, the following proportions will be included: Proportion of participants invited into the trials and subsequently screened for eligibility.Proportion of participants screened for eligibility in the trials and subsequently found to be eligible for inclusion.Proportion of participants found eligible for study and subsequently randomised into the trials.

### Dealing with missing data {#s3e4}

Missing means and SDs of post-treatment measurement scores will be requested from authors. The intention-to-treat principle will be followed as far as possible, analysing all patients as they were randomised. Sensitivity analysis will be conducted by temporarily dropping studies with high attrition in at least one arm (≥30%) from the analysis.

### Assessment of heterogeneity {#s3e5}

The presence of statistically significant heterogeneity will be examined by calculating the Q statistic with the quantification of the degree of heterogeneity calculated using the I^2^ statistic.[@R72] [@R73] If substantial heterogeneity is found (I^2^ value ≥50%), possible causes will be examined through subgroup analyses.

### Funnel asymmetry {#s3e6}

To investigate sources of possible bias (publication bias, language bias, inclusion of small studies with poor methodological rigour, heterogeneity), funnel plot asymmetry will be examined using Egger\'s Test of the Intercept,[@R74] where a minimum of 10 studies are included within the analysis.[@R75] Separate funnel plots will be calculated for each of the main outcomes (depression, anxiety, psychological distress and mental health-related quality of life). Effect sizes for each outcome will also be calculated taking into account the potential of bias using the trim and fill procedure.[@R76]

### Sensitivity analysis {#s3e7}

Sensitivity analysis will be conducted by Temporarily dropping small studies (n≤20 across conditions).Individually omitting each study from the meta-analysis to examine whether the effect size was biased by the inclusion of any particular study.Selective outcome reporting bias,[@R77] will be examined using the maximum bias-bound approach,[@R78] [@R79] with new treatment effects and CIs calculated by the addition of the bias-bound value to the original pooled effects.[@R78] [@R79]

### Moderator analysis {#s3e8}

Moderator analysis will be undertaken to examine intervention components, methodological components and participant characteristics of studies associated with effectiveness, when number of studies permits. Specifically, the following moderators will be examined: Dementia subtype;Baseline severity of cognitive impairment;Psychological model intervention based on;Mode of delivery (eg, individual, dyadic or group);Baseline severity of depression, anxiety, psychological distress or mental health-related quality of life;Treatment setting;Recruitment setting;Type of control condition;Length of follow-up.

If sufficient data are available, subgroup analysis, or meta-regression[@R67] will be conducted to examine moderators. With heterogeneity being anticipated, random effects will be adopted with Q and I^2^ reported as measures of heterogeneity. It should be noted that moderator analysis only provides correlational, not casual, data.[@R80] Any significant findings should be examined through further primary research.[@R81]

Discussion {#s4}
==========

Currently, there is no comprehensive review of psychological interventions for people with dementia or MCI that systematically examines: Several outcomes relating to psychological well-being, such as depression, anxiety, mental health-related quality of life and psychological distress.The quality of the available evidence.Effectiveness of recruitment strategies used.Effectiveness and clinical and methodological components associated with effectiveness.

This review will therefore examine the effectiveness of psychological interventions targeting psychological well-being for people experiencing dementia or MCI, identify clinical and methodological moderators of effect size alongside strategies associated with successful recruitment. With respect to these objectives, this review seeks to meet important objectives within phase I of the revised MRC guidance concerning the development of complex interventions.[@R82] It represents the first step towards developing a new psychological treatment for difficulties with psychological well-being in people with dementia, identifying important methodological uncertainties (eg, successful recruitment methods; appropriate comparator arms) to inform the design of a phase II feasibility study.

**Contributors:** PF and JW conceived and designed the study protocol and wrote the manuscript. JM provided statistical expertise and contributed to the review design and assisted in the drafting of the manuscript. MA and CD made contributions to the design, critical evaluation of intellectual content and assisted with drafting the manuscript. All authors have approved the final manuscript.

**Funding:** This paper is supported by funding provided by Cornwall Partnership NHS Foundation Trust (CFT), South West Peninsula Academic Health Sciences Network (SWAHSN), and the University of Exeter. JM was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South West Peninsula.

**Disclaimer:** The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

**Competing interests:** None declared.

**Provenance and peer review:** Not commissioned; externally peer reviewed.
